SI9600102A - Quinazoline derivatives - Google Patents
Quinazoline derivatives Download PDFInfo
- Publication number
- SI9600102A SI9600102A SI9600102A SI9600102A SI9600102A SI 9600102 A SI9600102 A SI 9600102A SI 9600102 A SI9600102 A SI 9600102A SI 9600102 A SI9600102 A SI 9600102A SI 9600102 A SI9600102 A SI 9600102A
- Authority
- SI
- Slovenia
- Prior art keywords
- amine
- quinazolin
- phenyl
- ethynyl
- alkyl
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- -1 4-(substitutedphenylamino)quinazoline Chemical class 0.000 claims abstract description 217
- 150000001875 compounds Chemical class 0.000 claims abstract description 111
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 150000001412 amines Chemical class 0.000 claims description 28
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 25
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 14
- 125000003282 alkyl amino group Chemical group 0.000 claims description 14
- 239000001301 oxygen Substances 0.000 claims description 14
- 239000011593 sulfur Substances 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 claims description 8
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical group C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- MTLKTHNRZJKPRP-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-6-(2-methoxyethoxy)quinazolin-7-yl]oxyethanol Chemical compound N1=CN=C2C=C(OCCO)C(OCCOC)=CC2=C1NC1=CC=CC(C#C)=C1 MTLKTHNRZJKPRP-UHFFFAOYSA-N 0.000 claims description 4
- XSMVZQAPXNUGBP-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethyl acetate Chemical compound C=12C=C(OCCOC(C)=O)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 XSMVZQAPXNUGBP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- TZHTWWZUWBDHPB-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-6-(2-methoxyethoxy)quinazolin-7-yl]oxyethyl acetate Chemical compound N1=CN=C2C=C(OCCOC(C)=O)C(OCCOC)=CC2=C1NC1=CC=CC(C#C)=C1 TZHTWWZUWBDHPB-UHFFFAOYSA-N 0.000 claims description 3
- YWSAEKIQJPQSDJ-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-hydroxyethoxy)quinazolin-6-yl]oxyethanol Chemical compound C=12C=C(OCCO)C(OCCO)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 YWSAEKIQJPQSDJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- NRKMCAKKJSZIRN-UHFFFAOYSA-N 4-n-(3-ethynylphenyl)quinazoline-4,6-diamine Chemical compound C12=CC(N)=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 NRKMCAKKJSZIRN-UHFFFAOYSA-N 0.000 claims description 3
- MLFVZJQGCZIVJI-UHFFFAOYSA-N 4-n-(3-ethynylphenyl)quinazoline-4,7-diamine Chemical compound N=1C=NC2=CC(N)=CC=C2C=1NC1=CC=CC(C#C)=C1 MLFVZJQGCZIVJI-UHFFFAOYSA-N 0.000 claims description 3
- AZMJCKIZWVLDEH-UHFFFAOYSA-N 6,7-diethoxy-n-(3-ethynylphenyl)-2h-quinazolin-1-amine Chemical compound C1=2C=C(OCC)C(OCC)=CC=2C=NCN1NC1=CC=CC(C#C)=C1 AZMJCKIZWVLDEH-UHFFFAOYSA-N 0.000 claims description 3
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 3
- XOTGKYTUNDYTBS-UHFFFAOYSA-N N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 XOTGKYTUNDYTBS-UHFFFAOYSA-N 0.000 claims description 3
- 150000001345 alkine derivatives Chemical class 0.000 claims description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- OVBFNQKSLJYVCB-UHFFFAOYSA-N n-(4-ethynylphenyl)-6,7-dimethoxyquinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(C#C)C=C1 OVBFNQKSLJYVCB-UHFFFAOYSA-N 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 125000005544 phthalimido group Chemical group 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims description 2
- KOQIAZNBAWFSQM-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethanol Chemical compound C=12C=C(OCCO)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KOQIAZNBAWFSQM-UHFFFAOYSA-N 0.000 claims description 2
- RPBDPTCBOMUIEM-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)quinazolin-6-yl]guanidine Chemical compound C12=CC(NC(=N)N)=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 RPBDPTCBOMUIEM-UHFFFAOYSA-N 0.000 claims description 2
- OPZQXOBOVGSGMM-UHFFFAOYSA-N 6,7-bis(2-chloroethoxy)-n-(3-ethynylphenyl)quinazolin-4-amine Chemical compound C=12C=C(OCCCl)C(OCCCl)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 OPZQXOBOVGSGMM-UHFFFAOYSA-N 0.000 claims description 2
- KNIMCHSAQRHRKH-UHFFFAOYSA-N 6,7-dibutoxy-n-(3-ethynylphenyl)-2h-quinazolin-1-amine Chemical compound C1=2C=C(OCCCC)C(OCCCC)=CC=2C=NCN1NC1=CC=CC(C#C)=C1 KNIMCHSAQRHRKH-UHFFFAOYSA-N 0.000 claims description 2
- DBLVDARHJKFUSK-UHFFFAOYSA-N 6-(2-chloroethoxy)-n-(3-ethynylphenyl)-7-(2-methoxyethoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCCl)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 DBLVDARHJKFUSK-UHFFFAOYSA-N 0.000 claims description 2
- BIHHIONDWPZXJC-UHFFFAOYSA-N 7-(2-chloroethoxy)-n-(3-ethynylphenyl)-6-(2-methoxyethoxy)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCCl)C(OCCOC)=CC2=C1NC1=CC=CC(C#C)=C1 BIHHIONDWPZXJC-UHFFFAOYSA-N 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910021386 carbon form Inorganic materials 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- MJGHBVDYEIMCDA-UHFFFAOYSA-N methyl 4-(3-ethynylanilino)quinazoline-6-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 MJGHBVDYEIMCDA-UHFFFAOYSA-N 0.000 claims description 2
- YVEQUSIQTPNUHB-UHFFFAOYSA-N n-(3-ethynyl-2-methylphenyl)-6,7-bis(2-methoxyethoxy)-2h-quinazolin-1-amine Chemical compound C1=2C=C(OCCOC)C(OCCOC)=CC=2C=NCN1NC1=CC=CC(C#C)=C1C YVEQUSIQTPNUHB-UHFFFAOYSA-N 0.000 claims description 2
- FFNSJZNWHNDAKT-UHFFFAOYSA-N n-(3-ethynyl-4-fluorophenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=C(F)C(C#C)=C1 FFNSJZNWHNDAKT-UHFFFAOYSA-N 0.000 claims description 2
- UEKLAZGZLXRYAO-UHFFFAOYSA-N n-(3-ethynyl-4-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(C#C)=C1 UEKLAZGZLXRYAO-UHFFFAOYSA-N 0.000 claims description 2
- FKTOOVAYMNBBOM-UHFFFAOYSA-N n-(3-ethynylphenyl)-6,7-di(propan-2-yloxy)-2h-quinazolin-1-amine Chemical compound C1=2C=C(OC(C)C)C(OC(C)C)=CC=2C=NCN1NC1=CC=CC(C#C)=C1 FKTOOVAYMNBBOM-UHFFFAOYSA-N 0.000 claims description 2
- XNMSCKOLUZHGET-UHFFFAOYSA-N n-(3-ethynylphenyl)-6-methylsulfonylquinazolin-4-amine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 XNMSCKOLUZHGET-UHFFFAOYSA-N 0.000 claims description 2
- AWQMPORAKHHXOC-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-methoxyquinazolin-4-amine Chemical compound N=1C=NC2=CC(OC)=CC=C2C=1NC1=CC=CC(C#C)=C1 AWQMPORAKHHXOC-UHFFFAOYSA-N 0.000 claims description 2
- PXVOMAUMUFQFKF-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-nitroquinazolin-4-amine Chemical compound N=1C=NC2=CC([N+](=O)[O-])=CC=C2C=1NC1=CC=CC(C#C)=C1 PXVOMAUMUFQFKF-UHFFFAOYSA-N 0.000 claims description 2
- LBAXXGJEHLZEQP-UHFFFAOYSA-N n-(3-ethynylphenyl)-[1,3]dioxolo[4,5-g]quinazolin-8-amine Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCOC=4C=C3N=CN=2)=C1 LBAXXGJEHLZEQP-UHFFFAOYSA-N 0.000 claims description 2
- MZSAGCRPYHVVDD-UHFFFAOYSA-N n-(5-ethynyl-2-methylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC(C#C)=CC=C1C MZSAGCRPYHVVDD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 26
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- DUGLQQONGNNEMW-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]acetamide Chemical compound C=12C=C(CC(N)=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 DUGLQQONGNNEMW-UHFFFAOYSA-N 0.000 claims 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- COYVNRXIBHVWOA-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-propan-2-yloxyquinazolin-6-yl]acetamide Chemical compound C=12C=C(CC(N)=O)C(OC(C)C)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 COYVNRXIBHVWOA-UHFFFAOYSA-N 0.000 claims 1
- TYRDQXAAPHCGHJ-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-propoxyquinazolin-6-yl]acetamide Chemical compound C=12C=C(CC(N)=O)C(OCCC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 TYRDQXAAPHCGHJ-UHFFFAOYSA-N 0.000 claims 1
- OLQYOMSHERWQMA-UHFFFAOYSA-N 2-[7-ethoxy-4-(3-ethynylanilino)quinazolin-6-yl]acetamide Chemical compound C=12C=C(CC(N)=O)C(OCC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 OLQYOMSHERWQMA-UHFFFAOYSA-N 0.000 claims 1
- NWUMMKLVEFBCRV-UHFFFAOYSA-N 2-[[1-(3-ethynyl-2-methylanilino)-7-(2-hydroxyethoxy)-2h-quinazolin-6-yl]oxy]ethanol Chemical compound C1=CC=C(C#C)C(C)=C1NN1C2=CC(OCCO)=C(OCCO)C=C2C=NC1 NWUMMKLVEFBCRV-UHFFFAOYSA-N 0.000 claims 1
- BLEIGNISAJGLGG-UHFFFAOYSA-N 2-[[1-(3-ethynylanilino)-7-(2-hydroxyethoxy)-2h-quinazolin-6-yl]oxy]ethanol Chemical compound C1=2C=C(OCCO)C(OCCO)=CC=2C=NCN1NC1=CC=CC(C#C)=C1 BLEIGNISAJGLGG-UHFFFAOYSA-N 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- XCMVOGXJGDEPQM-UHFFFAOYSA-N 3-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]propanamide Chemical compound C=12C=C(CCC(N)=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 XCMVOGXJGDEPQM-UHFFFAOYSA-N 0.000 claims 1
- HZDFRVLTROVMEI-UHFFFAOYSA-N 3-[4-(3-ethynylanilino)-7-propan-2-yloxyquinazolin-6-yl]propanamide Chemical compound C=12C=C(CCC(N)=O)C(OC(C)C)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 HZDFRVLTROVMEI-UHFFFAOYSA-N 0.000 claims 1
- OIESHIYYNQZRCL-UHFFFAOYSA-N 3-[4-(3-ethynylanilino)-7-propoxyquinazolin-6-yl]propanamide Chemical compound C=12C=C(CCC(N)=O)C(OCCC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 OIESHIYYNQZRCL-UHFFFAOYSA-N 0.000 claims 1
- JIKUZGKMYUACPU-UHFFFAOYSA-N 3-[7-ethoxy-4-(3-ethynylanilino)quinazolin-6-yl]propanamide Chemical compound C=12C=C(CCC(N)=O)C(OCC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 JIKUZGKMYUACPU-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- SRGSZEVWWPMFLC-UHFFFAOYSA-N methyl 4-(3-ethynylanilino)quinazoline-7-carboxylate Chemical compound N=1C=NC2=CC(C(=O)OC)=CC=C2C=1NC1=CC=CC(C#C)=C1 SRGSZEVWWPMFLC-UHFFFAOYSA-N 0.000 claims 1
- RMTOBWAVMBQAOO-UHFFFAOYSA-N n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-2h-quinazolin-1-amine Chemical compound C1=2C=C(OCCOC)C(OCCOC)=CC=2C=NCN1NC1=CC=CC(C#C)=C1 RMTOBWAVMBQAOO-UHFFFAOYSA-N 0.000 claims 1
- YHGQPRLZLURJKG-UHFFFAOYSA-N n-(3-ethynylphenyl)-6,7-dimethoxy-2h-quinazolin-1-amine Chemical compound C1=2C=C(OC)C(OC)=CC=2C=NCN1NC1=CC=CC(C#C)=C1 YHGQPRLZLURJKG-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 138
- 239000000047 product Substances 0.000 description 129
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 100
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 73
- 239000007787 solid Substances 0.000 description 64
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 239000000203 mixture Substances 0.000 description 46
- 239000011541 reaction mixture Substances 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 238000004128 high performance liquid chromatography Methods 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 27
- 239000012267 brine Substances 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 24
- 239000011734 sodium Substances 0.000 description 22
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 239000002585 base Substances 0.000 description 20
- 125000005843 halogen group Chemical group 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 18
- NNKQLUVBPJEUOR-UHFFFAOYSA-N 3-ethynylaniline Chemical compound NC1=CC=CC(C#C)=C1 NNKQLUVBPJEUOR-UHFFFAOYSA-N 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000012458 free base Substances 0.000 description 14
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 9
- 108060006698 EGF receptor Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- ZPJLDMNVDPGZIU-UHFFFAOYSA-N 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline Chemical compound C1=NC(Cl)=C2C=C(OCCOC)C(OCCOC)=CC2=N1 ZPJLDMNVDPGZIU-UHFFFAOYSA-N 0.000 description 8
- LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 8
- 102000001301 EGF receptor Human genes 0.000 description 8
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 8
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 230000010933 acylation Effects 0.000 description 5
- 238000005917 acylation reaction Methods 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 150000003246 quinazolines Chemical class 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
- HFGVHQGBDDTDIJ-UHFFFAOYSA-N 4-chloro-7-(2-chloroethoxy)-6-(2-methoxyethoxy)quinazoline Chemical compound N1=CN=C2C=C(OCCCl)C(OCCOC)=CC2=C1Cl HFGVHQGBDDTDIJ-UHFFFAOYSA-N 0.000 description 3
- UACQHSQWXWUFLT-UHFFFAOYSA-N 4-fluoro-3-(2-trimethylsilylethynyl)aniline Chemical compound C[Si](C)(C)C#CC1=CC(N)=CC=C1F UACQHSQWXWUFLT-UHFFFAOYSA-N 0.000 description 3
- XSLSFNALFKUARJ-UHFFFAOYSA-N 6,7-bis(2-methoxyethoxy)-1h-quinazolin-2-one Chemical compound C1=NC(=O)NC2=C1C=C(OCCOC)C(OCCOC)=C2 XSLSFNALFKUARJ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 3
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- ZOAIGCHJWKDIPJ-UHFFFAOYSA-M caesium acetate Chemical compound [Cs+].CC([O-])=O ZOAIGCHJWKDIPJ-UHFFFAOYSA-M 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012256 powdered iron Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000005694 sulfonylation reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- UBUGNWMTGOQPCM-UHFFFAOYSA-N 2-[7-(2-acetyloxyethoxy)-4-(3-ethynylanilino)quinazolin-6-yl]oxyethyl acetate Chemical compound C=12C=C(OCCOC(C)=O)C(OCCOC(=O)C)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 UBUGNWMTGOQPCM-UHFFFAOYSA-N 0.000 description 2
- LSBFEKPBXBBTCL-UHFFFAOYSA-N 2-[7-chloro-4-(3-ethynylanilino)quinazolin-6-yl]sulfanylacetonitrile Chemical compound C=12C=C(SCC#N)C(Cl)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 LSBFEKPBXBBTCL-UHFFFAOYSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- CUNYDQJCQAWKLK-UHFFFAOYSA-N 3-ethynylaniline;hydrochloride Chemical compound Cl.NC1=CC=CC(C#C)=C1 CUNYDQJCQAWKLK-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WXAZLCUYDRYLFC-UHFFFAOYSA-N 4-chloro-6,7-bis(2-chloroethoxy)quinazoline Chemical compound C1=NC(Cl)=C2C=C(OCCCl)C(OCCCl)=CC2=N1 WXAZLCUYDRYLFC-UHFFFAOYSA-N 0.000 description 2
- RORJMEOQKVOQBC-UHFFFAOYSA-N 4-chloro-6-(2-chloroethoxy)-7-(2-methoxyethoxy)quinazoline Chemical compound C1=NC(Cl)=C2C=C(OCCCl)C(OCCOC)=CC2=N1 RORJMEOQKVOQBC-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000021235 carbamoylation Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- KBPUBCVJHFXPOC-UHFFFAOYSA-N ethyl 3,4-dihydroxybenzoate Chemical compound CCOC(=O)C1=CC=C(O)C(O)=C1 KBPUBCVJHFXPOC-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 230000006103 sulfonylation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NLJDBTZLVTWXRG-UHFFFAOYSA-N tert-butylazanium;iodide Chemical compound [I-].CC(C)(C)[NH3+] NLJDBTZLVTWXRG-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- XRKUMSQNWPGUTF-UHFFFAOYSA-N trimethyl-[2-(3-nitrophenyl)ethynyl]silane Chemical compound C[Si](C)(C)C#CC1=CC=CC([N+]([O-])=O)=C1 XRKUMSQNWPGUTF-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000007738 vacuum evaporation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- AFQFCFYQEIWLKJ-UHFFFAOYSA-N 1-[2-[4-(3-ethynylanilino)-6-(2-methoxyethoxy)quinazolin-7-yl]oxyethyl]pyridin-4-one;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCN3C=CC(=O)C=C3)C(OCCOC)=CC2=C1NC1=CC=CC(C#C)=C1 AFQFCFYQEIWLKJ-UHFFFAOYSA-N 0.000 description 1
- KYJWZIMGVWQUID-UHFFFAOYSA-N 1-[2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethyl]pyridin-4-one;hydrochloride Chemical compound Cl.C=12C=C(OCCN3C=CC(=O)C=C3)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KYJWZIMGVWQUID-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- FWIROFMBWVMWLB-UHFFFAOYSA-N 1-bromo-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(Br)=C1 FWIROFMBWVMWLB-UHFFFAOYSA-N 0.000 description 1
- ZDFBKZUDCQQKAC-UHFFFAOYSA-N 1-bromo-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1 ZDFBKZUDCQQKAC-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical class C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 1
- HCPVYBCAYPMANM-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)ethanesulfonyl chloride Chemical compound C1=CC=C2C(=O)N(CCS(=O)(=O)Cl)C(=O)C2=C1 HCPVYBCAYPMANM-UHFFFAOYSA-N 0.000 description 1
- FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 description 1
- LZZLMZTVTUJGEC-UHFFFAOYSA-N 2-[(7-chloro-4-oxo-1h-quinazolin-6-yl)sulfanyl]acetamide Chemical compound N1=CNC(=O)C2=C1C=C(Cl)C(SCC(=O)N)=C2 LZZLMZTVTUJGEC-UHFFFAOYSA-N 0.000 description 1
- DIPPSATVOCYFSS-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-6-(2-methoxyethoxy)quinazolin-7-yl]oxyethanol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCO)C(OCCOC)=CC2=C1NC1=CC=CC(C#C)=C1 DIPPSATVOCYFSS-UHFFFAOYSA-N 0.000 description 1
- BUOXOWNQZVIETJ-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethanol;hydrochloride Chemical compound Cl.C=12C=C(OCCO)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 BUOXOWNQZVIETJ-UHFFFAOYSA-N 0.000 description 1
- OPFZHICTNRDQQU-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)quinazolin-6-yl]guanidine;hydrochloride Chemical compound Cl.C12=CC(NC(=N)N)=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 OPFZHICTNRDQQU-UHFFFAOYSA-N 0.000 description 1
- UDSSKXAFALXYCP-UHFFFAOYSA-N 2-methyl-3-(2-trimethylsilylethynyl)aniline Chemical compound CC1=C(N)C=CC=C1C#C[Si](C)(C)C UDSSKXAFALXYCP-UHFFFAOYSA-N 0.000 description 1
- XLIAOKABBIHDOI-UHFFFAOYSA-N 2-methyl-5-(2-trimethylsilylethynyl)aniline Chemical compound CC1=CC=C(C#C[Si](C)(C)C)C=C1N XLIAOKABBIHDOI-UHFFFAOYSA-N 0.000 description 1
- YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine Chemical class C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IILVSKMKMOJHMA-UHFFFAOYSA-N 3-bromo-2-methylaniline Chemical compound CC1=C(N)C=CC=C1Br IILVSKMKMOJHMA-UHFFFAOYSA-N 0.000 description 1
- KOWPUNQBGWIERF-UHFFFAOYSA-N 3-bromo-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Br)=C1 KOWPUNQBGWIERF-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- HWMVCSBQJWRQNF-UHFFFAOYSA-N 3-ethynyl-4-fluoroaniline Chemical compound NC1=CC=C(F)C(C#C)=C1 HWMVCSBQJWRQNF-UHFFFAOYSA-N 0.000 description 1
- QRZXFNFMRVWNDG-UHFFFAOYSA-N 4-(3-ethynylanilino)-6-(2-methoxyethoxy)quinazolin-7-ol Chemical compound N1=CN=C2C=C(O)C(OCCOC)=CC2=C1NC1=CC=CC(C#C)=C1 QRZXFNFMRVWNDG-UHFFFAOYSA-N 0.000 description 1
- SDYAJRBHPPWHSF-UHFFFAOYSA-N 4-azidoaniline;hydrochloride Chemical compound Cl.NC1=CC=C(N=[N+]=[N-])C=C1 SDYAJRBHPPWHSF-UHFFFAOYSA-N 0.000 description 1
- KZNXALJXBRSMFL-UHFFFAOYSA-N 4-bromo-1-methyl-2-nitrobenzene Chemical compound CC1=CC=C(Br)C=C1[N+]([O-])=O KZNXALJXBRSMFL-UHFFFAOYSA-N 0.000 description 1
- HGMQPDNSSYTATF-UHFFFAOYSA-N 4-chloro-6,7-diethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OCC)C(OCC)=CC2=N1 HGMQPDNSSYTATF-UHFFFAOYSA-N 0.000 description 1
- LZOSFEDULGODDH-UHFFFAOYSA-N 4-chloro-6-nitroquinazoline Chemical compound N1=CN=C(Cl)C2=CC([N+](=O)[O-])=CC=C21 LZOSFEDULGODDH-UHFFFAOYSA-N 0.000 description 1
- GUQZHZBMDPEBQG-UHFFFAOYSA-N 4-chloro-7-methoxyquinazoline Chemical compound ClC1=NC=NC2=CC(OC)=CC=C21 GUQZHZBMDPEBQG-UHFFFAOYSA-N 0.000 description 1
- CCCGYXZEVXWXAU-UHFFFAOYSA-N 4-chloro-7-nitroquinazoline Chemical compound ClC1=NC=NC2=CC([N+](=O)[O-])=CC=C21 CCCGYXZEVXWXAU-UHFFFAOYSA-N 0.000 description 1
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical compound C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- VZNUCJOYPXKLTA-UHFFFAOYSA-N 5-chlorobenzene-1,3-diamine Chemical compound NC1=CC(N)=CC(Cl)=C1 VZNUCJOYPXKLTA-UHFFFAOYSA-N 0.000 description 1
- UASVPQOWYLTXIE-UHFFFAOYSA-N 5-ethynyl-2-methylaniline Chemical compound CC1=CC=C(C#C)C=C1N UASVPQOWYLTXIE-UHFFFAOYSA-N 0.000 description 1
- MCJCPYXGLTWKGT-UHFFFAOYSA-N 6,7-bis(2-chloroethoxy)-n-(3-ethynylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OCCCl)C(OCCCl)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 MCJCPYXGLTWKGT-UHFFFAOYSA-N 0.000 description 1
- BDBRXILWISDQCT-UHFFFAOYSA-N 6,7-di(propan-2-yloxy)-1h-quinazolin-4-one Chemical compound N1=CNC(=O)C2=C1C=C(OC(C)C)C(OC(C)C)=C2 BDBRXILWISDQCT-UHFFFAOYSA-N 0.000 description 1
- YUQAWTZXQLPKQJ-UHFFFAOYSA-N 6,7-dibutoxy-1h-quinazolin-4-one Chemical compound N1=CNC(=O)C2=C1C=C(OCCCC)C(OCCCC)=C2 YUQAWTZXQLPKQJ-UHFFFAOYSA-N 0.000 description 1
- HAWMAPSKEIQTAR-UHFFFAOYSA-N 6,7-dibutoxy-n-(3-ethynylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OCCCC)C(OCCCC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 HAWMAPSKEIQTAR-UHFFFAOYSA-N 0.000 description 1
- CAKNVIMJJNHQLR-UHFFFAOYSA-N 6,7-diethoxy-1h-quinazolin-4-one Chemical compound N1=CNC(=O)C2=C1C=C(OCC)C(OCC)=C2 CAKNVIMJJNHQLR-UHFFFAOYSA-N 0.000 description 1
- ZQYYBJFCLFLXBU-UHFFFAOYSA-N 6,7-diethoxy-n-(3-ethynyl-2-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OCC)C(OCC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1C ZQYYBJFCLFLXBU-UHFFFAOYSA-N 0.000 description 1
- YVTPAGRDUZRXKY-UHFFFAOYSA-N 6,7-diethoxy-n-(3-ethynylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OCC)C(OCC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 YVTPAGRDUZRXKY-UHFFFAOYSA-N 0.000 description 1
- NQFZBXSVTMDWFQ-UHFFFAOYSA-N 6-(2-chloroethoxy)-n-(3-ethynylphenyl)-7-(2-methoxyethoxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OCCCl)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 NQFZBXSVTMDWFQ-UHFFFAOYSA-N 0.000 description 1
- HHXRZTKQJGLXLG-UHFFFAOYSA-N 6-(2-ethoxyethoxy)-n-(3-ethynylphenyl)-7-(2-methoxyethoxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCOC)C(OCCOCC)=CC2=C1NC1=CC=CC(C#C)=C1 HHXRZTKQJGLXLG-UHFFFAOYSA-N 0.000 description 1
- BACJUPWRBIZKTC-UHFFFAOYSA-N 6-chloro-7-(2-methoxyethylsulfanyl)-1h-quinazolin-4-one Chemical compound N1=CNC(=O)C2=C1C=C(SCCOC)C(Cl)=C2 BACJUPWRBIZKTC-UHFFFAOYSA-N 0.000 description 1
- NOFVNLZQAOGUIT-UHFFFAOYSA-N 6-methoxy-1h-quinazolin-4-one Chemical compound N1=CNC(=O)C2=CC(OC)=CC=C21 NOFVNLZQAOGUIT-UHFFFAOYSA-N 0.000 description 1
- JUCDXPIFJIVICL-UHFFFAOYSA-N 6-methyl-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC(C)=CC=C21 JUCDXPIFJIVICL-UHFFFAOYSA-N 0.000 description 1
- NMNMIARUPWAQPX-UHFFFAOYSA-N 6-methylsulfonyl-1h-quinazolin-4-one Chemical compound N1=CNC(=O)C2=CC(S(=O)(=O)C)=CC=C21 NMNMIARUPWAQPX-UHFFFAOYSA-N 0.000 description 1
- GBQJODHTQRFZEL-UHFFFAOYSA-N 7-(2-chloroethoxy)-n-(3-ethynylphenyl)-6-(2-methoxyethoxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCCl)C(OCCOC)=CC2=C1NC1=CC=CC(C#C)=C1 GBQJODHTQRFZEL-UHFFFAOYSA-N 0.000 description 1
- VYKOEQIDDPSCMR-UHFFFAOYSA-N 7-bromo-n-(3-ethynylphenyl)-6-methylsulfanylquinazolin-4-amine Chemical compound N1=CN=C2C=C(Br)C(SC)=CC2=C1NC1=CC=CC(C#C)=C1 VYKOEQIDDPSCMR-UHFFFAOYSA-N 0.000 description 1
- GDJUFRYOYCJPMY-UHFFFAOYSA-N 7-chloro-4-(3-ethynylanilino)quinazoline-6-carbonitrile Chemical compound C=12C=C(C#N)C(Cl)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GDJUFRYOYCJPMY-UHFFFAOYSA-N 0.000 description 1
- NRECGTITQNKAHG-UHFFFAOYSA-N 7-chloro-6-(2,5-dichlorophenyl)sulfanyl-n-(3-ethynylphenyl)quinazolin-4-amine Chemical compound ClC1=CC=C(Cl)C(SC=2C(=CC3=NC=NC(NC=4C=C(C=CC=4)C#C)=C3C=2)Cl)=C1 NRECGTITQNKAHG-UHFFFAOYSA-N 0.000 description 1
- URDYTQYZXZKBQT-UHFFFAOYSA-N 7-chloro-6-nitro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=C1C=C(Cl)C([N+](=O)[O-])=C2 URDYTQYZXZKBQT-UHFFFAOYSA-N 0.000 description 1
- XPVPLOIYNJSVQH-UHFFFAOYSA-N 7-chloro-n-(3-ethynylphenyl)-6-(4-fluorophenoxy)quinazolin-4-amine Chemical compound C1=CC(F)=CC=C1OC(C(=CC1=NC=N2)Cl)=CC1=C2NC1=CC=CC(C#C)=C1 XPVPLOIYNJSVQH-UHFFFAOYSA-N 0.000 description 1
- ZZHNBKOVSVWDIM-UHFFFAOYSA-N 7-chloro-n-(3-ethynylphenyl)-6-nitroquinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(Cl)C([N+](=O)[O-])=CC2=C1NC1=CC=CC(C#C)=C1 ZZHNBKOVSVWDIM-UHFFFAOYSA-N 0.000 description 1
- QVSGVNAEZGBBSW-UHFFFAOYSA-N 7-propylsulfanyl-1h-quinazolin-4-one Chemical compound N1=CNC(=O)C=2C1=CC(SCCC)=CC=2 QVSGVNAEZGBBSW-UHFFFAOYSA-N 0.000 description 1
- RZCJSVRGPHXBSM-UHFFFAOYSA-N 8-chloro-[1,3]dioxolo[4,5-g]quinazoline Chemical compound C1=C2C(Cl)=NC=NC2=CC2=C1OCO2 RZCJSVRGPHXBSM-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- CMPMEOMXRPVUIB-UHFFFAOYSA-N C(#C)C=1C=C(C=CC1)NC1=NC=NC2=CC(=C(C=C12)OC=C)OCCOC.Cl.C(#C)C=1C=C(C=CC1)NC1=NC=NC2=CC(=C(C=C12)O)OCCOC Chemical compound C(#C)C=1C=C(C=CC1)NC1=NC=NC2=CC(=C(C=C12)OC=C)OCCOC.Cl.C(#C)C=1C=C(C=CC1)NC1=NC=NC2=CC(=C(C=C12)O)OCCOC CMPMEOMXRPVUIB-UHFFFAOYSA-N 0.000 description 1
- OLZZJGGINQLVND-UHFFFAOYSA-N CC1=CC=CC=C1NC#C[Si](C)(C)C Chemical compound CC1=CC=CC=C1NC#C[Si](C)(C)C OLZZJGGINQLVND-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- HGGWQPDCGPVTBR-UHFFFAOYSA-N Cl.ClC1=C(C=C2C(=NC=NC2=C1)NC1=CC(=CC=C1)C#C)[N+](=O)[O-].C(#C)C=1C=C(C=CC1)NC1=NC=NC2=CC(=C(C=C12)[N+](=O)[O-])OC Chemical compound Cl.ClC1=C(C=C2C(=NC=NC2=C1)NC1=CC(=CC=C1)C#C)[N+](=O)[O-].C(#C)C=1C=C(C=CC1)NC1=NC=NC2=CC(=C(C=C12)[N+](=O)[O-])OC HGGWQPDCGPVTBR-UHFFFAOYSA-N 0.000 description 1
- YDBWDHGWDCAWCG-UHFFFAOYSA-N Cl.ClC1=C(C=C2C(=NC=NC2=C1)NC1=CC(=CC=C1)C#C)[N+](=O)[O-].Cl.NC=1C=C2C(=NC=NC2=CC1Cl)NC1=CC(=CC=C1)C#C Chemical compound Cl.ClC1=C(C=C2C(=NC=NC2=C1)NC1=CC(=CC=C1)C#C)[N+](=O)[O-].Cl.NC=1C=C2C(=NC=NC2=CC1Cl)NC1=CC(=CC=C1)C#C YDBWDHGWDCAWCG-UHFFFAOYSA-N 0.000 description 1
- IZWOCRAGJGZYSI-UHFFFAOYSA-N ClC1=NC=NC2=CC(=C(C=C12)OC)OC.Cl.COC=1C=C2C(=NC=NC2=CC1OC)NC1=CC(=C(C=C1)F)C#C Chemical compound ClC1=NC=NC2=CC(=C(C=C12)OC)OC.Cl.COC=1C=C2C(=NC=NC2=CC1OC)NC1=CC(=C(C=C1)F)C#C IZWOCRAGJGZYSI-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- KBGHOVYDLRMBIT-UHFFFAOYSA-N N-(3-ethynylphenyl)-6-nitroquinazolin-4-amine 4-N-(3-ethynylphenyl)quinazoline-4,6-diamine hydrochloride Chemical compound Cl.C(#C)C=1C=C(C=CC1)NC1=NC=NC2=CC=C(C=C12)[N+](=O)[O-].NC=1C=C2C(=NC=NC2=CC1)NC1=CC(=CC=C1)C#C KBGHOVYDLRMBIT-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- ZJOKWAWPAPMNIM-UHFFFAOYSA-N PD-153035 hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 ZJOKWAWPAPMNIM-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002065 Pluronic® P 105 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- WNAHYKISKIRRSY-UHFFFAOYSA-N azane;2-[2-[4-(3-ethynylanilino)-6-(2-methoxyethoxy)quinazolin-7-yl]oxyethylsulfanyl]acetic acid Chemical compound N.N1=CN=C2C=C(OCCSCC(O)=O)C(OCCOC)=CC2=C1NC1=CC=CC(C#C)=C1 WNAHYKISKIRRSY-UHFFFAOYSA-N 0.000 description 1
- PKNDVMFXUUWOFB-UHFFFAOYSA-N azane;2-[2-[4-(3-ethynylanilino)-6-(2-methoxyethoxy)quinazolin-7-yl]oxyethylsulfanyl]propanoic acid Chemical compound N.N1=CN=C2C=C(OCCSC(C)C(O)=O)C(OCCOC)=CC2=C1NC1=CC=CC(C#C)=C1 PKNDVMFXUUWOFB-UHFFFAOYSA-N 0.000 description 1
- KZHQEVQJKVQCIE-UHFFFAOYSA-N azane;2-[2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethylsulfanyl]acetic acid Chemical compound N.C=12C=C(OCCSCC(O)=O)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KZHQEVQJKVQCIE-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical class ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- VGFZRAVMWXHEJB-UHFFFAOYSA-N ethyl 3,4-bis(2-methoxyethoxy)benzoate Chemical compound CCOC(=O)C1=CC=C(OCCOC)C(OCCOC)=C1 VGFZRAVMWXHEJB-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000005027 hydroxyaryl group Chemical group 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940018564 m-phenylenediamine Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- IDHHMNQZABWRON-UHFFFAOYSA-N methyl 4-(3-ethynylanilino)quinazoline-6-carboxylate;hydrochloride Chemical compound Cl.C12=CC(C(=O)OC)=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 IDHHMNQZABWRON-UHFFFAOYSA-N 0.000 description 1
- NTNPIJPZPRBNDW-UHFFFAOYSA-N methyl 4-(3-ethynylanilino)quinazoline-7-carboxylate;hydrochloride Chemical compound Cl.N=1C=NC2=CC(C(=O)OC)=CC=C2C=1NC1=CC=CC(C#C)=C1 NTNPIJPZPRBNDW-UHFFFAOYSA-N 0.000 description 1
- ZFTPRYBXJRWOHZ-UHFFFAOYSA-N methyl 4-chloroquinazoline-6-carboxylate Chemical compound N1=CN=C(Cl)C2=CC(C(=O)OC)=CC=C21 ZFTPRYBXJRWOHZ-UHFFFAOYSA-N 0.000 description 1
- BYHDRGRVVXBJIP-UHFFFAOYSA-N methyl 4-chloroquinazoline-7-carboxylate Chemical compound ClC1=NC=NC2=CC(C(=O)OC)=CC=C21 BYHDRGRVVXBJIP-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- YBJOSAHERRCCJW-UHFFFAOYSA-N n-(3-ethynyl-2-methylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1C YBJOSAHERRCCJW-UHFFFAOYSA-N 0.000 description 1
- PPLYDLMRYZIHOR-UHFFFAOYSA-N n-(3-ethynyl-2-methylphenyl)-6,7-dimethoxyquinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1C PPLYDLMRYZIHOR-UHFFFAOYSA-N 0.000 description 1
- YHBVAFFTMUOBGK-UHFFFAOYSA-N n-(3-ethynyl-4-fluorophenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=C(F)C(C#C)=C1 YHBVAFFTMUOBGK-UHFFFAOYSA-N 0.000 description 1
- DEPCDHDAWBLYFX-UHFFFAOYSA-N n-(3-ethynyl-5-fluorophenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC(F)=CC(C#C)=C1 DEPCDHDAWBLYFX-UHFFFAOYSA-N 0.000 description 1
- QHLZFEIRZFUFLS-UHFFFAOYSA-N n-(3-ethynylphenyl)-6,7-di(propan-2-yloxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OC(C)C)C(OC(C)C)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 QHLZFEIRZFUFLS-UHFFFAOYSA-N 0.000 description 1
- WLPMLPRHPSNTHR-UHFFFAOYSA-N n-(3-ethynylphenyl)-6,7-dimethoxyquinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 WLPMLPRHPSNTHR-UHFFFAOYSA-N 0.000 description 1
- BLHGKLOYJPGTTE-UHFFFAOYSA-N n-(3-ethynylphenyl)-6-(2-imidazol-1-ylethoxy)-7-(2-methoxyethoxy)quinazolin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C=C(OCCN3C=NC=C3)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 BLHGKLOYJPGTTE-UHFFFAOYSA-N 0.000 description 1
- HMKJWRGRNHPARW-UHFFFAOYSA-N n-(3-ethynylphenyl)-6-methoxyquinazolin-4-amine;hydrochloride Chemical compound Cl.C12=CC(OC)=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 HMKJWRGRNHPARW-UHFFFAOYSA-N 0.000 description 1
- PLILRSOXLSXQQW-UHFFFAOYSA-N n-(3-ethynylphenyl)-6-methylquinazolin-4-amine;hydrochloride Chemical compound Cl.C12=CC(C)=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 PLILRSOXLSXQQW-UHFFFAOYSA-N 0.000 description 1
- PWYVDPHPGLWLSL-UHFFFAOYSA-N n-(3-ethynylphenyl)-6-methylsulfonylquinazolin-4-amine;hydrochloride Chemical compound Cl.C12=CC(S(=O)(=O)C)=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 PWYVDPHPGLWLSL-UHFFFAOYSA-N 0.000 description 1
- YCKNNOOOLDLHGY-UHFFFAOYSA-N n-(3-ethynylphenyl)-6-nitroquinazolin-4-amine;hydrochloride Chemical compound Cl.C12=CC([N+](=O)[O-])=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 YCKNNOOOLDLHGY-UHFFFAOYSA-N 0.000 description 1
- FXNPOBUEIRDARI-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-(2-imidazol-1-ylethoxy)-6-(2-methoxyethoxy)quinazolin-4-amine;dihydrochloride Chemical compound Cl.Cl.N1=CN=C2C=C(OCCN3C=NC=C3)C(OCCOC)=CC2=C1NC1=CC=CC(C#C)=C1 FXNPOBUEIRDARI-UHFFFAOYSA-N 0.000 description 1
- VITDPUGQQDQGEF-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-methoxyquinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC(OC)=CC=C2C=1NC1=CC=CC(C#C)=C1 VITDPUGQQDQGEF-UHFFFAOYSA-N 0.000 description 1
- QNXPBWBRUTVOIE-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-nitroquinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC([N+](=O)[O-])=CC=C2C=1NC1=CC=CC(C#C)=C1 QNXPBWBRUTVOIE-UHFFFAOYSA-N 0.000 description 1
- MANKXCCTWMBZAA-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-propylsulfanylquinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC(SCCC)=CC=C2C=1NC1=CC=CC(C#C)=C1 MANKXCCTWMBZAA-UHFFFAOYSA-N 0.000 description 1
- WMJUQSKPKWEBOC-UHFFFAOYSA-N n-(3-ethynylphenyl)-[1,3]dioxolo[4,5-g]quinazolin-8-amine;hydrochloride Chemical compound Cl.C#CC1=CC=CC(NC=2C3=CC=4OCOC=4C=C3N=CN=2)=C1 WMJUQSKPKWEBOC-UHFFFAOYSA-N 0.000 description 1
- RSGPYKWXSSTIGC-UHFFFAOYSA-N n-(4-azidophenyl)-6,7-dimethoxyquinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(N=[N+]=[N-])C=C1 RSGPYKWXSSTIGC-UHFFFAOYSA-N 0.000 description 1
- VIKZXHATNZVSPZ-UHFFFAOYSA-N n-(5-ethynyl-2-methylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC(C#C)=CC=C1C VIKZXHATNZVSPZ-UHFFFAOYSA-N 0.000 description 1
- NPWROGXMBGWEJT-UHFFFAOYSA-N n-[4-(3-ethynylanilino)quinazolin-6-yl]methanesulfonamide Chemical compound C12=CC(NS(=O)(=O)C)=CC=C2N=CN=C1NC1=CC=CC(C#C)=C1 NPWROGXMBGWEJT-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- FJVZDOGVDJCCCR-UHFFFAOYSA-M potassium periodate Chemical compound [K+].[O-]I(=O)(=O)=O FJVZDOGVDJCCCR-UHFFFAOYSA-M 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- XAIQADWTFHMCOS-UHFFFAOYSA-N quinazoline-6-carbonitrile Chemical compound N1=CN=CC2=CC(C#N)=CC=C21 XAIQADWTFHMCOS-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- KIMPPGSMONZDMN-UHFFFAOYSA-N sodium;dihydrogen phosphite Chemical compound [Na+].OP(O)[O-] KIMPPGSMONZDMN-UHFFFAOYSA-N 0.000 description 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000004272 stretch cell Anatomy 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- WFVAXJGPWUHVSD-UHFFFAOYSA-N trimethyl-[2-(4-methyl-3-nitrophenyl)ethynyl]silane Chemical compound CC1=CC=C(C#C[Si](C)(C)C)C=C1[N+]([O-])=O WFVAXJGPWUHVSD-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41330095A | 1995-03-30 | 1995-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI9600102A true SI9600102A (en) | 1997-02-28 |
Family
ID=23636708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9600102A SI9600102A (en) | 1995-03-30 | 1996-03-29 | Quinazoline derivatives |
Country Status (43)
| Country | Link |
|---|---|
| EP (5) | EP3103799B1 (h) |
| JP (1) | JP3088018B2 (h) |
| KR (1) | KR100232335B1 (h) |
| CN (1) | CN1066142C (h) |
| AP (1) | AP735A (h) |
| AR (1) | AR002723A1 (h) |
| AT (2) | ATE446955T1 (h) |
| AU (2) | AU703638B2 (h) |
| BR (1) | BR9601200B1 (h) |
| CA (1) | CA2216796C (h) |
| CO (1) | CO4410333A1 (h) |
| CZ (2) | CZ295145B6 (h) |
| DE (3) | DE122005000053I2 (h) |
| DK (1) | DK0817775T3 (h) |
| EG (1) | EG24229A (h) |
| ES (2) | ES2332984T3 (h) |
| FI (1) | FI120646B (h) |
| FR (1) | FR06C0010I2 (h) |
| GR (1) | GR3037070T3 (h) |
| HR (1) | HRP960147B1 (h) |
| HU (2) | HU229120B1 (h) |
| IL (7) | IL189037A (h) |
| LU (1) | LU91209I2 (h) |
| MA (1) | MA23831A1 (h) |
| MX (1) | MX9707453A (h) |
| MY (1) | MY117896A (h) |
| NL (1) | NL300214I2 (h) |
| NO (2) | NO308740B1 (h) |
| NZ (1) | NZ286263A (h) |
| OA (1) | OA10277A (h) |
| PE (1) | PE43897A1 (h) |
| PL (1) | PL186843B1 (h) |
| PT (1) | PT817775E (h) |
| RU (2) | RU2694252C2 (h) |
| SA (1) | SA96160707B1 (h) |
| SG (1) | SG43262A1 (h) |
| SI (1) | SI9600102A (h) |
| SK (2) | SK283762B6 (h) |
| TR (1) | TR199600265A1 (h) |
| TW (1) | TW454000B (h) |
| UA (1) | UA44254C2 (h) |
| WO (1) | WO1996030347A1 (h) |
| ZA (1) | ZA962522B (h) |
Families Citing this family (548)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| TW321649B (h) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| DE69613367T2 (de) * | 1995-04-27 | 2002-04-18 | Astrazeneca Ab, Soedertaelje | Chinazolin derivate |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SI0880508T1 (en) | 1996-02-13 | 2003-10-31 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
| GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| AU2912997A (en) * | 1996-06-24 | 1998-01-14 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6090096A (en) | 1997-04-23 | 2000-07-18 | Heartport, Inc. | Antegrade cardioplegia catheter and method |
| DE19743435A1 (de) | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| AU759691C (en) * | 1998-04-29 | 2004-04-29 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine mesylate anhydrate and monohydrate |
| US6384223B1 (en) | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
| ATE399541T1 (de) | 1998-08-18 | 2008-07-15 | Univ California | Epidermale wachstumsfaktor rezeptor antagonisten zur behandlung stark vermehrter schleimsekretion in der lunge |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| RS49836B (sr) * | 1999-03-31 | 2008-08-07 | Pfizer Products Inc., | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| HUP0201900A3 (en) | 1999-06-21 | 2003-02-28 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof |
| ATE377597T1 (de) * | 1999-07-09 | 2007-11-15 | Glaxo Group Ltd | Anilinochinazoline als protein-tyrosin- kinasehemmer |
| US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
| HUP0204413A3 (en) * | 1999-09-21 | 2003-07-28 | Astrazeneca Ab | Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them |
| GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| GB9925958D0 (en) * | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
| DE60039206D1 (de) | 1999-11-05 | 2008-07-24 | Astrazeneca Ab | Neue Quinazolin-Derivate |
| US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| DE60121931T2 (de) | 2000-04-07 | 2007-03-01 | Astrazeneca Ab | Chinazolinverbindungen |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| EP1170011A1 (en) * | 2000-07-06 | 2002-01-09 | Boehringer Ingelheim International GmbH | Novel use of inhibitors of the epidermal growth factor receptor |
| CA2419301C (en) | 2000-08-21 | 2009-12-08 | Astrazeneca Ab | Quinazoline derivatives |
| RU2264389C3 (ru) | 2000-10-20 | 2018-06-01 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| JP4564713B2 (ja) | 2000-11-01 | 2010-10-20 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法 |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| EP3351246B8 (en) | 2001-02-19 | 2019-09-18 | Novartis Pharma AG | Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis |
| JP2002293773A (ja) * | 2001-03-30 | 2002-10-09 | Sumika Fine Chemicals Co Ltd | キナゾリン誘導体の製造方法 |
| RU2332415C2 (ru) * | 2001-04-27 | 2008-08-27 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, полезные в качестве ингибиторов протеинкиназы |
| AU2002345792A1 (en) | 2001-06-21 | 2003-01-08 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| EP1408980A4 (en) | 2001-06-21 | 2004-10-20 | Ariad Pharma Inc | NEW QUINAZOLINES AND THEIR USE |
| EP1483268A2 (en) | 2002-03-01 | 2004-12-08 | Pfizer Inc. | Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| JP5227492B2 (ja) | 2002-05-16 | 2013-07-03 | ノバルティス アーゲー | 癌におけるedgレセプター結合剤の使用 |
| UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| BR0312534A (pt) | 2002-07-15 | 2007-03-13 | Genentech Inc | método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura |
| CN101987871A (zh) | 2002-09-27 | 2011-03-23 | 赞科股份有限公司 | 优化的Fc变体及其产生方法 |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| JP4611745B2 (ja) * | 2002-11-20 | 2011-01-12 | アレイ バイオファーマ、インコーポレイテッド | ErbB2及びEGFR阻害剤としてのシアノグアニジン及びシアノアミジン |
| WO2004060400A1 (ja) * | 2003-01-06 | 2004-07-22 | Mitsubishi Pharma Corp | 上皮成長因子受容体を分子標的とする抗精神病薬 |
| GB0302882D0 (en) * | 2003-02-07 | 2003-03-12 | Univ Cardiff | Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss |
| US7148231B2 (en) * | 2003-02-17 | 2006-12-12 | Hoffmann-La Roche Inc. | [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| ATE508747T1 (de) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
| AU2004230209A1 (en) * | 2003-04-16 | 2004-10-28 | F. Hoffmann-La Roche Ag | Quinazoline compounds useful as p38 kinase inhibitors |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| ES2467160T3 (es) | 2003-05-19 | 2014-06-12 | Irm Llc | Compuestos y composiciones inmunosupresores |
| CA2527680A1 (en) | 2003-05-30 | 2005-06-02 | Astrazeneca Uk Limited | Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor |
| EP1638600A4 (en) | 2003-06-09 | 2008-06-11 | Samuel Waksal | PROCESS FOR INHIBITING RECEPTOR TYROSINE KINASES WITH AN EXTRACELLULAR ANTAGONIST AND AN INTRA CELLULAR ANTAGONIST |
| CN100378101C (zh) | 2003-06-10 | 2008-04-02 | 霍夫曼-拉罗奇有限公司 | 1.3.4-三氮杂-非那烯和1,3,4,6-四氮杂非那烯衍生物 |
| KR101218213B1 (ko) | 2003-07-03 | 2013-01-04 | 시토비아 인크. | 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린 |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| KR100953246B1 (ko) * | 2003-08-14 | 2010-04-16 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
| BRPI0413745A (pt) * | 2003-08-18 | 2006-10-24 | Pfizer Prod Inc | horário mde dosagem para agentes anticancerìgenos erbb2 |
| JP2007504122A (ja) | 2003-08-29 | 2007-03-01 | ファイザー・インク | 新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体 |
| DK1667991T3 (da) | 2003-09-16 | 2008-08-18 | Astrazeneca Ab | Quinazolinderivater som tyrosinkinaseinhibitorer |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| EP3858387A1 (en) | 2003-11-06 | 2021-08-04 | Seagen Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| CN100450998C (zh) | 2003-11-11 | 2009-01-14 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| GEP20084572B (en) | 2003-12-23 | 2008-12-25 | Pfizer | Novel quinoline derivatives |
| US7632840B2 (en) | 2004-02-03 | 2009-12-15 | Astrazeneca Ab | Quinazoline compounds for the treatment of hyperproliferative disorders |
| ES2554330T3 (es) * | 2004-02-19 | 2015-12-18 | Rexahn Pharmaceuticals, Inc. | Derivados de quinazolina y uso terapéutico de los mismos |
| PT1735348E (pt) | 2004-03-19 | 2012-07-24 | Imclone Llc | Anticorpo anti-receptor do factor de crescimento humano |
| CN101501211A (zh) | 2004-03-31 | 2009-08-05 | 综合医院公司 | 测定癌症对表皮生长因子受体靶向性治疗反应性的方法 |
| EP1735307B1 (en) | 2004-04-07 | 2012-08-29 | Novartis AG | Inhibitors of iap |
| BRPI0510717B8 (pt) | 2004-05-06 | 2021-05-25 | Bioresponse Llc | uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr) |
| RU2404810C9 (ru) | 2004-06-01 | 2015-06-20 | Дженентек, Инк. | Конъюгаты антитело-лекарственное средство и способы |
| EP2277595A3 (en) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
| BRPI0510674A (pt) | 2004-07-15 | 2007-12-26 | Xencor Inc | variantes fc otimizadas |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| CN101001629B (zh) | 2004-09-17 | 2010-05-05 | 卫材R&D管理有限公司 | 药物组合物 |
| WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1817340B1 (en) | 2004-11-12 | 2012-05-16 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| ATE501148T1 (de) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US7989486B2 (en) | 2004-12-30 | 2011-08-02 | Bioresponse, L.L.C. | Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions |
| CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| US7625911B2 (en) | 2005-01-12 | 2009-12-01 | Mai De Ltd. | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion |
| KR20150083139A (ko) | 2005-01-21 | 2015-07-16 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
| US20080161251A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| GB0501999D0 (en) * | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| DK1850874T3 (da) | 2005-02-23 | 2013-11-11 | Genentech Inc | Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab |
| DK1854789T3 (da) * | 2005-02-23 | 2013-10-21 | Shionogi & Co | Quinazolinderivat med tyrosin-kinase inhibitorisk aktivitet |
| CA2599210A1 (en) | 2005-02-26 | 2006-08-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| ME01222B (me) | 2005-02-28 | 2013-06-20 | Eisai R&D Man Co Ltd | Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera |
| MX2007012778A (es) * | 2005-04-12 | 2008-01-11 | Elan Pharma Int Ltd | Formulaciones de derivados de quinazolina nanoparticuladas. |
| CN1854130B (zh) * | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| PL2100618T3 (pl) | 2005-06-17 | 2014-07-31 | Imclone Llc | Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości |
| US7557190B2 (en) | 2005-07-08 | 2009-07-07 | Xencor, Inc. | Optimized proteins that target Ep-CAM |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| EP1917528B1 (en) | 2005-08-24 | 2011-08-17 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| EP1928861B1 (en) | 2005-09-20 | 2010-11-17 | AstraZeneca AB | 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| WO2007052850A1 (ja) | 2005-11-07 | 2007-05-10 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質とc-kitキナーゼ阻害物質との併用 |
| CA2833852C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| EP2275103B1 (en) | 2005-11-21 | 2014-04-23 | Novartis AG | mTOR inhibitors in the treatment of endocrine tumors |
| WO2007060691A2 (en) * | 2005-11-23 | 2007-05-31 | Natco Pharma Limited | A novel process for the preparation of erlotinib |
| US7825137B2 (en) * | 2005-12-05 | 2010-11-02 | Pfizer Inc. | Method of treating abnormal cell growth |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| AU2007212447B2 (en) | 2006-02-03 | 2013-02-21 | Imclone Llc | IGF-IR antagonists as adjuvants for treatment of prostate cancer |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| CN102671196B (zh) | 2006-04-05 | 2014-12-03 | 诺华股份有限公司 | 用于治疗癌症的治疗剂的组合 |
| KR20140020367A (ko) | 2006-04-05 | 2014-02-18 | 노파르티스 아게 | 암을 치료하기 위한 bcr-abl/c-kit/pdgf-r tk 억제제를 포함하는 조합물 |
| TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| JP2009534400A (ja) | 2006-04-19 | 2009-09-24 | ノバルティス アクチエンゲゼルシャフト | インダゾール化合物およびcdc7の阻害方法 |
| KR20090007635A (ko) | 2006-05-09 | 2009-01-19 | 노파르티스 아게 | 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도 |
| CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| WO2007138613A2 (en) * | 2006-05-25 | 2007-12-06 | Vittal Mallya Scientific Research Foundation | A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride |
| WO2007138612A2 (en) * | 2006-05-25 | 2007-12-06 | Vittal Mallya Scientific Research Foundation | A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4- yl]-(3-ethynylphenyl)amine hydrochloride |
| WO2008012105A1 (en) * | 2006-07-28 | 2008-01-31 | Synthon B.V. | Crystalline erlotinib |
| EP2059536B1 (en) | 2006-08-14 | 2014-01-08 | Xencor, Inc. | Optimized antibodies that target cd19 |
| EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| EP2845912A1 (en) | 2006-09-12 | 2015-03-11 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic marker |
| CA2663599A1 (en) | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
| KR20090073121A (ko) | 2006-09-29 | 2009-07-02 | 노파르티스 아게 | Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘 |
| WO2008041118A2 (en) | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8372856B2 (en) * | 2006-10-27 | 2013-02-12 | Synthon Bv | Hydrates of erlotinib hydrochloride |
| BRPI0717753B1 (pt) | 2006-10-27 | 2022-04-12 | Bioresponse, Llc | Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| WO2008076949A2 (en) * | 2006-12-15 | 2008-06-26 | Concert Pharmaceuticals Inc. | Quinazoline derivatives and methods of treatment |
| AU2008205847A1 (en) | 2007-01-19 | 2008-07-24 | Eisai R & D Management Co., Ltd. | Composition for treatment of pancreatic cancer |
| CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
| WO2008095847A1 (de) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| CN101245050A (zh) | 2007-02-14 | 2008-08-20 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的盐 |
| EP2491923A3 (en) | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| WO2008102369A1 (en) | 2007-02-21 | 2008-08-28 | Natco Pharma Limited | Novel polymorphs of erlotinib hydrochloride and method of preparation |
| NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| KR101441930B1 (ko) * | 2007-04-04 | 2014-09-19 | 시플라 리미티드 | 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법 |
| EP3392273A1 (en) | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| SI2171090T1 (sl) | 2007-06-08 | 2013-07-31 | Genentech, Inc. | Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| WO2009030224A2 (de) * | 2007-09-07 | 2009-03-12 | Schebo Biotech Ag | Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen |
| MX2010004625A (es) | 2007-10-29 | 2010-05-20 | Natco Pharma Ltd | Nuevos derivados de 4(tetrazol-5-il)-quinazolina como agentes anticancerosos. |
| AU2008345242B2 (en) | 2007-10-31 | 2014-02-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| CL2008003449A1 (es) | 2007-11-21 | 2010-02-19 | Imclone Llc | Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer. |
| EP2240475B1 (en) | 2007-12-20 | 2013-09-25 | Novartis AG | Thiazole derivatives used as pi 3 kinase inhibitors |
| KR101640161B1 (ko) | 2008-01-18 | 2016-07-15 | 낫코 파마 리미티드 | 암과 관련된 질환의 치료에 유용한 6,7-디알콕시 퀴나졸린 유도체 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
| KR20100111291A (ko) | 2008-02-07 | 2010-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법 |
| PL2268612T3 (pl) | 2008-03-24 | 2015-02-27 | Novartis Ag | Arylosulfonamidowe inhibitory metaloproteinaz macierzy |
| CN101544609A (zh) | 2008-03-25 | 2009-09-30 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的结晶形式 |
| ES2519474T3 (es) | 2008-03-26 | 2014-11-07 | Novartis Ag | Inhibidores de las desacetilasas B basados en hidroxamato |
| WO2009121042A1 (en) * | 2008-03-28 | 2009-10-01 | Concert Pharmaceuticals, Inc. | Quinazoline derivatives and methods of treatment |
| EA019183B1 (ru) | 2008-05-13 | 2014-01-30 | Астразенека Аб | Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина |
| ES2430590T3 (es) | 2008-05-14 | 2013-11-21 | Genomic Health, Inc. | Predictores de la respuesta de pacientes al tratamiento con inhibidores del receptor del EGF |
| CN101584696A (zh) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| DE102008031039A1 (de) | 2008-06-30 | 2009-12-31 | Dömling, Alexander, Priv.-Doz. Dr. | Tarceva zur Anwendung in der Organtransplantation. |
| EP2313397B1 (de) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| ES2704986T3 (es) | 2008-10-16 | 2019-03-21 | Celator Pharmaceuticals Inc | Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab |
| MX2011004824A (es) | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | Uso de derivados de butano catecólico en terapia contra el cáncer. |
| KR20110075015A (ko) | 2008-11-11 | 2011-07-05 | 일라이 릴리 앤드 캄파니 | P70 s6 키나제 억제제 및 egfr 억제제 조합 요법 |
| HUE034819T2 (en) | 2008-12-18 | 2018-02-28 | Novartis Ag | 1- (4- {1 - [(E) -4-Cyclohexyl-3-trifluoromethyl-benzyloxyimino] -ethyl} -2-ethyl-benzyl) -azetidine-3-carboxylic acid hemifumarate salt for treatment of diseases mediated by lymphocytes |
| WO2010080455A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | New salts |
| ES2531831T3 (es) | 2008-12-18 | 2015-03-20 | Novartis Ag | Forma polimórfica del ácido 1-(4-{1-[(E)-4-ciclohexil-3-trifluorometil-benciloxiimino]-etil}-2-etil-bencil)-azetidin-3-carboxilico |
| WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
| PT2391366E (pt) | 2009-01-29 | 2013-02-05 | Novartis Ag | Benzimidazoles substituídos para o tratamento de astrocitomas |
| EP2213281A1 (en) | 2009-02-02 | 2010-08-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
| WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012519281A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2010107968A1 (en) | 2009-03-18 | 2010-09-23 | Osi Pharmaceuticals, Inc. | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
| US8440823B2 (en) * | 2009-03-26 | 2013-05-14 | Ranbaxy Laboratories Limited | Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof |
| WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| DK2451445T3 (da) | 2009-07-06 | 2019-06-24 | Boehringer Ingelheim Int | Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens |
| US9050341B2 (en) * | 2009-07-14 | 2015-06-09 | Natco Pharma Limited | Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EP2464649A1 (en) | 2009-08-12 | 2012-06-20 | Novartis AG | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| EP2467141B1 (en) | 2009-08-17 | 2018-10-31 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| CA2771936A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| WO2011053779A2 (en) | 2009-10-30 | 2011-05-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
| PE20121471A1 (es) | 2009-11-04 | 2012-11-01 | Novartis Ag | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek |
| WO2011058164A1 (en) | 2009-11-13 | 2011-05-19 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| KR20120123299A (ko) | 2009-12-04 | 2012-11-08 | 제넨테크, 인크. | 다중특이적 항체, 항체 유사체, 조성물 및 방법 |
| KR20120102750A (ko) | 2009-12-08 | 2012-09-18 | 노파르티스 아게 | 헤테로시클릭 술폰아미드 유도체 |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| EP2348020A1 (en) | 2009-12-23 | 2011-07-27 | Esteve Química, S.A. | Preparation process of erlotinib |
| US8461328B2 (en) | 2010-01-12 | 2013-06-11 | Genentech, Inc. | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| CA2800230A1 (en) | 2010-03-04 | 2011-09-09 | Hospital District Of Southwest Finland | Method for selecting patients for treatment with an egfr inhibitor |
| EP2547338A2 (en) | 2010-03-17 | 2013-01-23 | F. Hoffmann-La Roche AG | Imidazopyridine compounds, compositions and methods of use |
| CA2794708C (en) | 2010-03-29 | 2021-11-16 | Zymeworks Inc. | Antibodies with enhanced or suppressed effector function |
| RU2012148699A (ru) | 2010-04-16 | 2014-05-27 | Дженентек, Инк. | Foxo3a как прогностический биомаркер для эффективности ингибитора пути киназы pi3k/акт |
| DE202010006543U1 (de) | 2010-05-07 | 2010-09-09 | Ratiopharm Gmbh | Erlotinibresinat |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| CA2799989A1 (en) | 2010-05-21 | 2011-11-24 | Shanghai Institute Of Pharmaceutical Industry | Polycyclic quinazolines, preparation thereof, and use thereof |
| WO2011147102A1 (zh) * | 2010-05-28 | 2011-12-01 | 翔真生物科技股份有限公司 | 6,7-取代基-4-苯胺类喹唑啉的合成方法 |
| BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| JP5948597B2 (ja) * | 2010-07-23 | 2016-07-06 | ジェネリクス・[ユーケー]・リミテッド | 純粋なエルロチニブ |
| AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
| CA2812087A1 (en) | 2010-09-15 | 2012-03-22 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
| EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| IT1402029B1 (it) | 2010-10-14 | 2013-08-28 | Italiana Sint Spa | Procedimento per la preparazione di erlotinib |
| EP2637692A4 (en) | 2010-11-12 | 2014-09-10 | Scott & White Healthcare | ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8 |
| CN103313987A (zh) | 2010-11-19 | 2013-09-18 | 弗·哈夫曼-拉罗切有限公司 | 吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途 |
| EA024026B1 (ru) * | 2010-11-25 | 2016-08-31 | Рациофарм Гмбх | Новые соли и полиморфные формы афатиниба |
| DE102010053124A1 (de) | 2010-12-01 | 2012-06-06 | Volkswagen Ag | Kupplung, insbesondere für ein Getriebe eines Kraftfahrzeuges, vorzugsweise Doppelkupplung für ein automatisches oder automatisiertes Doppelkupplungsgetriebe |
| KR20130130030A (ko) | 2010-12-21 | 2013-11-29 | 노파르티스 아게 | Vps34 억제제로서의 비-헤테로아릴 화합물 |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| CN103476777B (zh) | 2011-01-31 | 2015-05-27 | 诺瓦提斯公司 | 新杂环衍生物 |
| US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| BR112013022552B1 (pt) | 2011-03-04 | 2021-11-23 | Newgen Therapeutics, Inc | Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit |
| AU2012225246B2 (en) | 2011-03-10 | 2016-01-21 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| GB201106870D0 (en) | 2011-04-26 | 2011-06-01 | Univ Belfast | Marker |
| EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
| WO2012155339A1 (zh) * | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| MX2013014398A (es) | 2011-06-09 | 2014-03-21 | Novartis Ag | Derivados de sulfonamida heterociclicos. |
| WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
| WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| CN102267952B (zh) * | 2011-06-21 | 2013-12-11 | 天津市汉康医药生物技术有限公司 | 喹唑啉类化合物、其制备方法和用途 |
| CN103608349A (zh) | 2011-06-27 | 2014-02-26 | 诺瓦提斯公司 | 四氢-吡啶并-嘧啶衍生物的固体形式和盐 |
| US8575339B2 (en) * | 2011-07-05 | 2013-11-05 | Xueheng Cheng | Derivatives of erlotinib |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| JP5855253B2 (ja) | 2011-08-12 | 2016-02-09 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | インダゾール化合物、組成物及び使用方法 |
| WO2013025446A2 (en) | 2011-08-12 | 2013-02-21 | Omeros Corporation | Anti-fzd10 monoclonal antibodies and methods for their use |
| WO2014081405A2 (en) | 2011-08-17 | 2014-05-30 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
| JP6297490B2 (ja) | 2011-08-31 | 2018-03-20 | ジェネンテック, インコーポレイテッド | 診断マーカー |
| ES2691650T3 (es) | 2011-09-15 | 2018-11-28 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met |
| CA2845409A1 (en) | 2011-09-20 | 2013-03-28 | Yingjie Lai | Imidazopyridine compounds, compositions and methods of use |
| CA2849120A1 (en) | 2011-09-30 | 2013-04-18 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
| HU230483B1 (hu) | 2011-10-10 | 2016-07-28 | Egis Gyógyszergyár Nyrt. | Erlotinib sók |
| US20140309229A1 (en) | 2011-10-13 | 2014-10-16 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
| CN104039790B (zh) | 2011-10-28 | 2016-04-13 | 诺华股份有限公司 | 嘌呤衍生物及它们在治疗疾病中的应用 |
| CN104080787B (zh) | 2011-11-29 | 2016-09-14 | 诺华股份有限公司 | 吡唑并吡咯烷化合物 |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| HUE036953T2 (hu) | 2011-12-22 | 2018-08-28 | Novartis Ag | 2,3-dihidro-benzo[1,4]oxazin-származékok és rokon vegyületek, mint foszfoinozitid-3-kináz (PI3K) inhibitorok például reumatoid arthritis kezelésére |
| US20150148377A1 (en) | 2011-12-22 | 2015-05-28 | Novartis Ag | Quinoline Derivatives |
| KR20140107575A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
| MX2014007725A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| KR20140107573A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
| EA201491264A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |
| AU2012355624A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| JO3357B1 (ar) | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
| JP6181089B2 (ja) | 2012-03-08 | 2017-08-16 | ハロザイム インコーポレイテッド | 条件依存活性抗上皮細胞増殖因子受容体抗体およびその使用方法 |
| CN104220457A (zh) | 2012-03-27 | 2014-12-17 | 霍夫曼-拉罗奇有限公司 | 涉及her3抑制剂的诊断和治疗 |
| RU2660354C2 (ru) | 2012-04-03 | 2018-07-05 | Новартис Аг | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| CN104349779A (zh) | 2012-05-16 | 2015-02-11 | 诺华股份有限公司 | Pi-3激酶抑制剂的剂量方案 |
| WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
| EP2861256B1 (en) | 2012-06-15 | 2019-10-23 | The Brigham and Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| US9593083B2 (en) | 2012-09-04 | 2017-03-14 | Shilpa Medicare Limited | Crystalline erlotinib hydrochloride process |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
| BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| WO2014118112A1 (en) | 2013-01-29 | 2014-08-07 | Synthon B.V. | Pharmaceutical composition comprising erlotinib hydrochloride |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
| US10035801B2 (en) | 2013-03-13 | 2018-07-31 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| HK1219421A1 (zh) | 2013-03-15 | 2017-04-07 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| US20160051556A1 (en) | 2013-03-21 | 2016-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| CN105611933B (zh) | 2013-09-05 | 2019-01-25 | 基因泰克公司 | 抗增生性化合物 |
| CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
| US20150071923A1 (en) | 2013-09-12 | 2015-03-12 | Ge Wei | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
| CA2924286C (en) | 2013-09-17 | 2022-06-21 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
| SG11201600028YA (en) | 2013-09-22 | 2016-02-26 | Calitor Sciences Llc | Substituted aminopyrimidine compounds and methods of use |
| TW201605857A (zh) | 2013-10-03 | 2016-02-16 | 赫孚孟拉羅股份公司 | Cdk8之醫療性抑制劑及其用途 |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| EP3076969B1 (en) | 2013-12-06 | 2021-09-01 | Novartis AG | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
| KR20160099092A (ko) | 2013-12-17 | 2016-08-19 | 제넨테크, 인크. | Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법 |
| AU2014364601A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| US9394281B2 (en) | 2014-03-28 | 2016-07-19 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| CA2943834A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| LT3126394T (lt) | 2014-03-31 | 2020-01-27 | F. Hoffmann-La Roche Ag | Antikūnai prieš ox40 ir jų naudojimo būdai |
| MX2016012893A (es) | 2014-04-03 | 2017-05-12 | Invictus Oncology Pvt Ltd | Sustancias terapéuticas combinadas supramoleculares. |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| BR112017001695A2 (pt) | 2014-07-31 | 2017-11-21 | Novartis Ag | terapia de combinação |
| JO3783B1 (ar) | 2014-08-28 | 2021-01-31 | Eisai R&D Man Co Ltd | مشتق كوينولين عالي النقاء وطريقة لإنتاجه |
| CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| EP3193866A1 (en) | 2014-09-19 | 2017-07-26 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
| CN107912040B (zh) | 2014-10-10 | 2021-04-06 | 基因泰克公司 | 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物 |
| WO2016059600A1 (en) | 2014-10-17 | 2016-04-21 | Novartis Ag | Combination of ceritinib with an egfr inhibitor |
| CA2908441A1 (en) | 2014-10-28 | 2016-04-28 | Cerbios-Pharma Sa | Process for the preparation of erlotinib |
| EP3215850B1 (en) | 2014-11-03 | 2019-07-03 | F. Hoffmann-La Roche AG | Assays for detecting t cell immune subsets and methods of use thereof |
| KR20170074246A (ko) | 2014-11-03 | 2017-06-29 | 제넨테크, 인크. | Ox40 효능제 치료의 효능 예측 및 평가용 방법 및 바이오마커 |
| KR20170072343A (ko) | 2014-11-06 | 2017-06-26 | 제넨테크, 인크. | Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법 |
| CN107108613B (zh) | 2014-11-10 | 2020-02-25 | 基因泰克公司 | 布罗莫结构域抑制剂及其用途 |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| CA2967368A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| EP3224258B1 (en) | 2014-11-27 | 2019-08-14 | Genentech, Inc. | 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| WO2016082879A1 (en) * | 2014-11-27 | 2016-06-02 | Synthon B.V. | Pharmaceutical composition comprising erlotinib hydrochloride |
| KR20170094165A (ko) | 2014-12-23 | 2017-08-17 | 제넨테크, 인크. | 화학요법-내성 암을 치료 및 진단하는 조성물 및 방법 |
| MY188938A (en) | 2014-12-24 | 2022-01-13 | Genentech Inc | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
| CN107208138A (zh) | 2014-12-30 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 用于癌症预后和治疗的方法和组合物 |
| JP6659703B2 (ja) | 2015-01-09 | 2020-03-04 | ジェネンテック, インコーポレイテッド | ピリダジノン誘導体および癌の処置におけるそれらの使用 |
| EP3242872B1 (en) | 2015-01-09 | 2019-07-03 | Genentech, Inc. | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer |
| WO2016112251A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
| WO2016123391A1 (en) | 2015-01-29 | 2016-08-04 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| CN107438593B (zh) | 2015-01-30 | 2020-10-30 | 基因泰克公司 | 治疗化合物及其用途 |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| BR112017017428A2 (pt) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | ?método para supressão do amargor de derivado de quinolina? |
| CN104725327B (zh) * | 2015-03-03 | 2017-08-25 | 山东大学 | 一种盐酸厄洛替尼的环保制备方法 |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| CA2981183A1 (en) | 2015-04-07 | 2016-10-13 | Greg Lazar | Antigen binding complex having agonistic activity and methods of use |
| CA2983282A1 (en) | 2015-05-12 | 2016-11-17 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| EP4335931A3 (en) | 2015-05-29 | 2024-06-19 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
| AU2016274585A1 (en) | 2015-06-08 | 2017-12-14 | Genentech, Inc. | Methods of treating cancer using anti-OX40 antibodies |
| AU2016274584A1 (en) | 2015-06-08 | 2018-01-04 | Genentech, Inc. | Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists |
| KR102705821B1 (ko) | 2015-06-16 | 2024-09-12 | 가부시키가이샤 프리즘 바이오랩 | 항암제 |
| CN116327953A (zh) | 2015-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| CN105017162B (zh) * | 2015-06-26 | 2017-10-27 | 陕西师范大学 | 4‑对丙烯基苯氨基喹唑啉衍生物及其在制备抗肿瘤药物中的应用 |
| SG11201801083UA (en) | 2015-08-20 | 2018-03-28 | Eisai R&D Man Co Ltd | Tumor therapeutic agent |
| CA2996233C (en) | 2015-08-26 | 2024-01-16 | Fundacion Del Sector Publico Estatal Centro Nacional De Investigaciones Oncologicas Carlos Iii (F.S.P. Cnio) | Condensed tricyclic compounds as protein kinase inhibitors |
| JP2018526376A (ja) | 2015-08-28 | 2018-09-13 | ノバルティス アーゲー | がんの治療または予防のための(a)サイクリン依存性キナーゼ4/6(cdk4/6)阻害剤のlee011(=リボシクリブ)および(b)上皮成長因子受容体(egfr)阻害剤のエルロチニブを含む医薬組み合わせ物 |
| HK1256912A1 (zh) | 2015-09-04 | 2019-10-04 | 台湾浩鼎生技股份有限公司 | 聚糖阵列以及使用方法 |
| JP2018527362A (ja) | 2015-09-11 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 置換されたヘテロアリール化合物および使用方法 |
| TWI811892B (zh) | 2015-09-25 | 2023-08-11 | 美商建南德克公司 | 抗tigit抗體及使用方法 |
| JP2018532750A (ja) | 2015-11-02 | 2018-11-08 | ノバルティス アーゲー | ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン |
| AU2016369528B2 (en) | 2015-12-16 | 2021-04-22 | Genentech, Inc. | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer |
| BR112018011029A2 (pt) | 2016-01-08 | 2018-11-21 | Hoffmann La Roche | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits |
| AU2017225854B2 (en) | 2016-02-29 | 2020-11-19 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| KR20180121786A (ko) | 2016-03-29 | 2018-11-08 | 오비아이 파머 인코퍼레이티드 | 항체, 제약 조성물 및 방법 |
| ES2850428T3 (es) | 2016-04-15 | 2021-08-30 | Hoffmann La Roche | Procedimientos de monitorización y tratamiento del cáncer |
| KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| MX2018012493A (es) | 2016-04-15 | 2019-06-06 | Genentech Inc | Métodos para controlar y tratar el cáncer. |
| TWI697333B (zh) | 2016-04-22 | 2020-07-01 | 台灣浩鼎生技股份有限公司 | 經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法 |
| EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| CN115028617A (zh) | 2016-05-24 | 2022-09-09 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
| WO2017205538A1 (en) | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Pyrazolopyridine derivatives for the treatment of cancer |
| JP7148504B2 (ja) | 2016-06-08 | 2022-10-05 | ゼンコー,インコーポレイティド | CD32Bに交差結合した抗CD19抗体を用いたIgG4関連疾患の治療 |
| WO2017214373A1 (en) | 2016-06-08 | 2017-12-14 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| KR20190067765A (ko) | 2016-07-27 | 2019-06-17 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| CN110062767B (zh) | 2016-07-29 | 2023-07-11 | 台湾浩鼎生技股份有限公司 | 人抗体、药物组合物和方法 |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| CN109476748B (zh) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
| WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| AU2017339517B2 (en) | 2016-10-06 | 2024-03-14 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
| WO2018078143A1 (en) | 2016-10-28 | 2018-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy |
| CN110267678A (zh) | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 抗mic抗体和使用方法 |
| TWI767959B (zh) | 2016-11-21 | 2022-06-21 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| CN116606261A (zh) | 2016-12-22 | 2023-08-18 | 美国安进公司 | Kras g12c抑制剂及其使用方法 |
| BR112019014127A2 (pt) | 2017-02-08 | 2020-02-11 | Eisai R&D Management Co., Ltd. | Composição farmacêutica para tratamento de tumores |
| WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CN106928069B (zh) * | 2017-03-21 | 2019-03-19 | 上海玉函化工有限公司 | 一种4,5-二(2-甲氧基乙氧基)-2-硝基苯甲酸乙酯的制备方法 |
| BR112019021411A2 (pt) | 2017-04-13 | 2020-05-05 | Hoffmann La Roche | métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| CN107200715B (zh) * | 2017-06-22 | 2020-05-29 | 陕西师范大学 | 喹唑啉衍生物及其在制备抗肿瘤药物中的应用 |
| MX2020000604A (es) | 2017-07-21 | 2020-09-10 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
| KR102713874B1 (ko) | 2017-08-11 | 2024-10-10 | 제넨테크, 인크. | 항-cd8 항체 및 이의 용도 |
| CA3075046A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| CN111373055B (zh) | 2017-09-08 | 2024-07-23 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| CN118459413A (zh) * | 2017-09-26 | 2024-08-09 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| EP3710001B1 (en) | 2017-10-27 | 2025-06-18 | University Of Virginia Patent Foundation | Compounds and methods for regulating, limiting, or inhibiting avil expression |
| ES2984919T3 (es) | 2017-11-06 | 2024-10-31 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
| EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
| US12174193B2 (en) | 2018-01-15 | 2024-12-24 | Epiaxis Therapeutics Pty Ltd | Agents and methods for predicting response to therapy |
| WO2019143874A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| BR112020015199A2 (pt) | 2018-01-26 | 2021-05-04 | Exelixis, Inc. | compostos para o tratamento de distúrbios dependentes de quinase |
| CN117820226A (zh) | 2018-01-26 | 2024-04-05 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| AU2019212800B2 (en) | 2018-01-26 | 2024-05-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| TWI660728B (zh) * | 2018-02-09 | 2019-06-01 | 國立交通大學 | 胺基喹唑啉衍生物及其醫藥組合物與用途 |
| US20200399376A1 (en) | 2018-02-26 | 2020-12-24 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| AU2019262599B2 (en) | 2018-05-04 | 2023-10-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| MA52564A (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
| WO2019226514A2 (en) | 2018-05-21 | 2019-11-28 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
| MX2020012731A (es) | 2018-06-01 | 2021-02-22 | Amgen Inc | Inhibidores de kras g12c y metodos para su uso. |
| WO2019241157A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
| SG11202012446UA (en) | 2018-06-23 | 2021-01-28 | Genentech Inc | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| CN110642796B (zh) * | 2018-06-27 | 2023-03-17 | 烟台药物研究所 | 一种喹唑啉类衍生物及其应用 |
| AU2019305637A1 (en) | 2018-07-18 | 2021-03-11 | Genentech, Inc. | Methods of treating lung cancer with a PD-1 axis binding antagonist, an antimetabolite, and a platinum agent |
| JP7535500B2 (ja) | 2018-09-03 | 2024-08-16 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Teadモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体 |
| EP3853611A1 (en) | 2018-09-19 | 2021-07-28 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for bladder cancer |
| CA3111809A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| WO2020068867A1 (en) | 2018-09-25 | 2020-04-02 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
| AU2019352741A1 (en) | 2018-10-04 | 2021-05-06 | Assistance Publique-Hôpitaux De Paris (Aphp) | EGFR inhibitors for treating keratodermas |
| US12404540B2 (en) | 2018-10-17 | 2025-09-02 | The University Of Queensland | Epigenetic biomarker and uses therefor |
| MX2021004348A (es) | 2018-10-18 | 2021-05-28 | Genentech Inc | Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide. |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
| WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| WO2020132653A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
| CN120398830A (zh) | 2018-12-20 | 2025-08-01 | 美国安进公司 | Kif18a抑制剂 |
| AU2019403488B2 (en) | 2018-12-20 | 2025-07-24 | Amgen Inc. | KIF18A inhibitors |
| AU2019407426A1 (en) | 2018-12-21 | 2021-07-22 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| BR112021016923A2 (pt) | 2019-02-27 | 2021-11-03 | Genentech Inc | Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits |
| AU2020227319A1 (en) | 2019-02-27 | 2021-09-09 | Epiaxis Therapeutics Pty Ltd | Methods and agents for assessing T-cell function and predicting response to therapy |
| KR20210146287A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
| US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| WO2020223233A1 (en) | 2019-04-30 | 2020-11-05 | Genentech, Inc. | Prognostic and therapeutic methods for colorectal cancer |
| CN114269376A (zh) | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 用抗pd-l1抗体治疗癌症的方法 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| UA129871C2 (uk) | 2019-05-21 | 2025-08-27 | Емджен Інк. | Тверді форми |
| CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| EP4007638A1 (en) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
| CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
| US20220289724A1 (en) | 2019-08-02 | 2022-09-15 | Amgen Inc. | Kif18a inhibitors |
| BR112022002518A2 (pt) | 2019-08-15 | 2022-07-19 | Black Diamond Therapeutics Inc | Compostos de alquinila quinazolina |
| TWI873176B (zh) | 2019-09-04 | 2025-02-21 | 美商建南德克公司 | Cd8結合劑及其用途 |
| AU2020351782A1 (en) | 2019-09-26 | 2022-04-21 | Exelixis, Inc. | Pyridone compounds and methods of use in the modulation of a protein kinase |
| JP2022548978A (ja) | 2019-09-27 | 2022-11-22 | ジェネンテック, インコーポレイテッド | 薬抗tigit及び抗pd-l1アンタゴニスト抗体を用いた処置のための投薬 |
| CA3155857A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| US20230024096A1 (en) | 2019-10-29 | 2023-01-26 | Hoffmann-La Roche Inc. | Bifunctional compounds for the treatment of cancer |
| CR20220240A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2022553859A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
| US20220389103A1 (en) | 2019-11-06 | 2022-12-08 | Genentech, Inc. | Diagnostic and therapeutic methods for treatment of hematologic cancers |
| PH12022551102A1 (en) | 2019-11-08 | 2023-11-20 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| EP4058435A1 (en) | 2019-11-13 | 2022-09-21 | Genentech, Inc. | Therapeutic compounds and methods of use |
| EP4058453A1 (en) | 2019-11-14 | 2022-09-21 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| AU2020383535A1 (en) | 2019-11-14 | 2022-05-05 | Amgen Inc. | Improved synthesis of KRAS G12C inhibitor compound |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| CA3164995A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN114929279A (zh) | 2020-01-07 | 2022-08-19 | 锐新医药公司 | Shp2抑制剂给药和治疗癌症的方法 |
| CN114980883A (zh) | 2020-01-20 | 2022-08-30 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
| TW202142230A (zh) | 2020-01-27 | 2021-11-16 | 美商建南德克公司 | 用於以抗tigit拮抗體抗體治療癌症之方法 |
| WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
| WO2021202959A1 (en) | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| EP4143345A1 (en) | 2020-04-28 | 2023-03-08 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
| MX2022015877A (es) | 2020-06-16 | 2023-01-24 | Genentech Inc | Metodos y composiciones para tratar cancer de mama triple negativo. |
| KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| EP4172621A1 (en) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| JP7741831B2 (ja) | 2020-06-30 | 2025-09-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び/又は死亡のリスクを予測するための方法 |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2022031749A1 (en) | 2020-08-03 | 2022-02-10 | Genentech, Inc. | Diagnostic and therapeutic methods for lymphoma |
| EP4196612A1 (en) | 2020-08-12 | 2023-06-21 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CN116847887A (zh) | 2020-08-27 | 2023-10-03 | 伊诺西治疗公司 | 治疗自身免疫性疾病和癌症的方法和组合物 |
| CN116209438A (zh) | 2020-09-03 | 2023-06-02 | 锐新医药公司 | 使用sos1抑制剂治疗具有shp2突变的恶性疾病 |
| CN116457358A (zh) | 2020-09-15 | 2023-07-18 | 锐新医药公司 | 作为ras抑制剂以治疗癌症的吲哚衍生物 |
| US12162893B2 (en) | 2020-09-23 | 2024-12-10 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| TW202446417A (zh) | 2020-10-05 | 2024-12-01 | 美商建南德克公司 | 用抗 fcrh5/抗 cd3 雙特異性抗體進行治療之給藥 |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
| MX2023009379A (es) | 2021-02-12 | 2023-10-10 | Hoffmann La Roche | Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer. |
| EP4294804A1 (en) | 2021-02-19 | 2023-12-27 | Exelixis, Inc. | Pyridone compounds and methods of use |
| AR125782A1 (es) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | Inhibidores de ras |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| JP2024520457A (ja) | 2021-05-25 | 2024-05-24 | エラスカ・インコーポレイテッド | 硫黄含有ヘテロ芳香族三環式kras阻害剤 |
| US20240293558A1 (en) | 2021-06-16 | 2024-09-05 | Erasca, Inc. | Kras inhibitor conjugates |
| JP2024528697A (ja) | 2021-07-20 | 2024-07-30 | エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ | 微細藻類由来の細胞外小胞、その調製および使用 |
| EP4384522A1 (en) | 2021-08-10 | 2024-06-19 | Erasca, Inc. | Selective kras inhibitors |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| EP4436969A2 (en) | 2021-11-24 | 2024-10-02 | Genentech, Inc. | Bicyclic therapeutic compounds and methods of use in the treatment of cancer |
| TW202332429A (zh) | 2021-11-24 | 2023-08-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
| JP2025500878A (ja) | 2021-12-17 | 2025-01-15 | ジェンザイム・コーポレーション | Shp2阻害剤としてのピラゾロピラジン化合物 |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| JP2025510910A (ja) | 2022-03-31 | 2025-04-15 | アストラゼネカ・アクチエボラーグ | 癌の処置のための、akt阻害剤との組み合わせにおける上皮成長因子受容体(egfr)チロシンキナーゼ阻害剤 |
| WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| IL316738A (en) | 2022-05-11 | 2024-12-01 | Genentech Inc | Dosage for treatment with anti-FCRH5/anti-CD3 bispecific antibodies |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| KR20250022133A (ko) | 2022-06-10 | 2025-02-14 | 레볼루션 메디슨즈, 인크. | 거대고리 ras 억제제 |
| WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| AU2023305619A1 (en) | 2022-07-13 | 2025-01-23 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| EP4558524A1 (en) | 2022-07-19 | 2025-05-28 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| EP4568960A1 (en) | 2022-08-11 | 2025-06-18 | F. Hoffmann-La Roche AG | Bicyclic tetrahydroazepine derivatives |
| AU2023322638A1 (en) | 2022-08-11 | 2024-11-28 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
| JP2025526683A (ja) | 2022-08-11 | 2025-08-15 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 二環式テトラヒドロチアゼピン誘導体 |
| PE20251399A1 (es) | 2022-08-11 | 2025-05-22 | Hoffmann La Roche | Derivados de tetrahidrotiazepina biciclicos |
| PE20251879A1 (es) | 2022-10-14 | 2025-07-22 | Black Diamond Therapeutics Inc | Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina |
| WO2024085242A2 (en) | 2022-10-21 | 2024-04-25 | Kawasaki Institute Of Industrial Promotion | Non-fouling or super stealth vesicle |
| WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
| WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
| WO2024173842A1 (en) | 2023-02-17 | 2024-08-22 | Erasca, Inc. | Kras inhibitors |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ras gtp水解之組合物及其用途 |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ras相關疾病或病症之組合療法 |
| WO2024233341A1 (en) | 2023-05-05 | 2024-11-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2024254455A1 (en) | 2023-06-08 | 2024-12-12 | Genentech, Inc. | Macrophage signatures for diagnostic and therapeutic methods for lymphoma |
| WO2025024257A1 (en) | 2023-07-21 | 2025-01-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202515614A (zh) | 2023-08-25 | 2025-04-16 | 美商建南德克公司 | 治療非小細胞肺癌之方法及組成物 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025176843A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU400048A1 (h) * | 1970-12-14 | 1973-10-03 | ||
| SU466233A1 (ru) * | 1973-06-08 | 1975-04-05 | Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе | Способ получени производных 2-метил-4-диалкиламиноалкиламинохиназолина |
| EP0584222B1 (en) | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| US5258518A (en) * | 1992-04-01 | 1993-11-02 | G. D. Searle & Co. | 2-substituted tertiary carbinol derivatives of deoxynojirimycin |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
-
1995
- 1995-06-06 WO PCT/IB1995/000436 patent/WO1996030347A1/en active IP Right Grant
- 1995-06-06 EP EP16171536.2A patent/EP3103799B1/en not_active Expired - Lifetime
- 1995-06-06 ES ES01104696T patent/ES2332984T3/es not_active Expired - Lifetime
- 1995-06-06 ES ES95918713T patent/ES2161290T3/es not_active Expired - Lifetime
- 1995-06-06 DE DE200512000053 patent/DE122005000053I2/de active Active
- 1995-06-06 EP EP95918713A patent/EP0817775B1/en not_active Expired - Lifetime
- 1995-06-06 PT PT95918713T patent/PT817775E/pt unknown
- 1995-06-06 MX MX9707453A patent/MX9707453A/es active IP Right Grant
- 1995-06-06 AT AT01104696T patent/ATE446955T1/de not_active IP Right Cessation
- 1995-06-06 DK DK95918713T patent/DK0817775T3/da active
- 1995-06-06 JP JP08529113A patent/JP3088018B2/ja not_active Expired - Lifetime
- 1995-06-06 EP EP10186213A patent/EP2295415A1/en not_active Ceased
- 1995-06-06 EP EP01104696A patent/EP1110953B1/en not_active Expired - Lifetime
- 1995-06-06 EP EP09174228.8A patent/EP2163546B1/en not_active Expired - Lifetime
- 1995-06-06 DE DE69522717T patent/DE69522717T2/de not_active Expired - Lifetime
- 1995-06-06 AT AT95918713T patent/ATE205483T1/de active
- 1995-06-06 CA CA002216796A patent/CA2216796C/en not_active Expired - Lifetime
- 1995-06-06 DE DE69536015T patent/DE69536015D1/de not_active Expired - Lifetime
-
1996
- 1996-03-05 TW TW085102699A patent/TW454000B/zh not_active IP Right Cessation
- 1996-03-07 AP APAP/P/1996/000788A patent/AP735A/en active
- 1996-03-21 IL IL189037A patent/IL189037A/en not_active IP Right Cessation
- 1996-03-21 IL IL11759896A patent/IL117598A/xx active Protection Beyond IP Right Term
- 1996-03-21 IL IL12999596A patent/IL129995A/xx not_active IP Right Cessation
- 1996-03-21 IL IL129994A patent/IL129994A/en not_active IP Right Cessation
- 1996-03-25 PE PE1996000207A patent/PE43897A1/es not_active IP Right Cessation
- 1996-03-25 SK SK387-96A patent/SK283762B6/sk not_active IP Right Cessation
- 1996-03-25 MA MA24190A patent/MA23831A1/fr unknown
- 1996-03-25 SK SK56-2003A patent/SK283763B6/sk not_active IP Right Cessation
- 1996-03-25 AR ARP960101903A patent/AR002723A1/es active IP Right Grant
- 1996-03-27 NZ NZ286263A patent/NZ286263A/en not_active IP Right Cessation
- 1996-03-28 CN CN96102992A patent/CN1066142C/zh not_active Expired - Lifetime
- 1996-03-28 EG EG26996A patent/EG24229A/xx active
- 1996-03-28 UA UA96031214A patent/UA44254C2/uk unknown
- 1996-03-29 BR BRPI9601200-5A patent/BR9601200B1/pt not_active IP Right Cessation
- 1996-03-29 MY MYPI96001194A patent/MY117896A/en unknown
- 1996-03-29 CZ CZ19972067A patent/CZ295145B6/cs not_active IP Right Cessation
- 1996-03-29 RU RU0096106055K patent/RU2694252C2/ru active Protection Beyond IP Right Term
- 1996-03-29 TR TR96/00265A patent/TR199600265A1/xx unknown
- 1996-03-29 ZA ZA9602522A patent/ZA962522B/xx unknown
- 1996-03-29 SI SI9600102A patent/SI9600102A/sl active Search and Examination
- 1996-03-29 AU AU50406/96A patent/AU703638B2/en not_active Expired
- 1996-03-29 RU RU0096106055A patent/RU2694252C3/ru active IP Right Grant
- 1996-03-29 HR HR960147A patent/HRP960147B1/xx not_active IP Right Cessation
- 1996-03-29 OA OA60807A patent/OA10277A/en unknown
- 1996-03-29 SG SG1996006639A patent/SG43262A1/en unknown
- 1996-03-29 CZ CZ1996931A patent/CZ294967B6/cs not_active IP Right Cessation
- 1996-03-29 NO NO961299A patent/NO308740B1/no not_active IP Right Cessation
- 1996-03-29 HU HU9600834A patent/HU229120B1/hu active Protection Beyond IP Right Term
- 1996-03-29 CO CO96015833A patent/CO4410333A1/es unknown
- 1996-03-30 SA SA96160707A patent/SA96160707B1/ar unknown
- 1996-03-30 KR KR1019960009659A patent/KR100232335B1/ko not_active Expired - Lifetime
-
1997
- 1997-09-29 PL PL96313541A patent/PL186843B1/pl unknown
- 1997-09-29 FI FI973832A patent/FI120646B/fi not_active IP Right Cessation
-
1999
- 1999-05-17 IL IL12999699A patent/IL129996A0/xx unknown
- 1999-05-17 IL IL12999599A patent/IL129995A0/xx unknown
- 1999-05-17 IL IL12999499A patent/IL129994A0/xx active IP Right Grant
- 1999-06-23 AU AU35854/99A patent/AU3585499A/en not_active Abandoned
-
2001
- 2001-10-30 GR GR20010401942T patent/GR3037070T3/el unknown
-
2005
- 2005-12-14 LU LU91209C patent/LU91209I2/fr unknown
-
2006
- 2006-01-02 NL NL300214C patent/NL300214I2/nl unknown
- 2006-03-06 NO NO2006004C patent/NO2006004I2/no unknown
- 2006-03-15 FR FR06C0010C patent/FR06C0010I2/fr active Active
-
2014
- 2014-01-21 HU HUS1400001C patent/HUS1400001I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9600102A (en) | Quinazoline derivatives | |
| USRE41065E1 (en) | Alkynl and azido-substituted 4-anilinoquinazolines | |
| US6395733B1 (en) | Heterocyclic ring-fused pyrimidine derivatives | |
| EP0831829B1 (en) | Heterocyclic ring-fused pyrimidine derivatives | |
| JP4012245B2 (ja) | キナゾリン誘導体 | |
| AU778961B2 (en) | Intermediates for the preparation of 4-(substituted phenylamino)quinazoline derivatives | |
| HK1231045A1 (en) | Quinazoline derivatives | |
| HK1231045A (en) | Quinazoline derivatives | |
| HK1042083A (en) | Quinazoline derivatives | |
| HK1141804A (en) | Quinazoline derivatives | |
| HK1038740B (en) | Quinazoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| OU01 | Decison according to article 73(1) ipa 1992, publication of decision on fulfilment of conditions on patentability |
Effective date: 20050304 |
|
| SP73 | Change of data on owner |
Owner name: PFIZER PRODUCTS INC.; US Effective date: 20060314 |
|
| LIQB | Entry of data on licence or sublicence in the register |
Effective date: 20090817 |
|
| SP73 | Change of data on owner |
Owner name: OSI PHARMACEUTICALS, INC.; US Effective date: 20091223 |
|
| SP73 | Change of data on owner |
Owner name: OSI PHARMACEUTICALS, LLC; US Effective date: 20160209 |